Skip to main content

BeiGene Enters $160 Million Deal for Rights to Seattle Genetics Cancer Molecule

BeiGene of Beijing announced a $160 million agreement for China/Asia rights to an advanced preclinical cancer candidate from Seattle Genetics. The candidate was not described, though Seattle Genetics said it expected to start clinical trials of the molecule in the first half of 2020. Seattle Genetics is known for its antibody drug conjugate cancer drugs. BeiGene will make up to $160 million in upfront and development milestone payments, plus pay royalties on sales. More details.... Stock Symbols: (NSDQ: BGNE; HK: 06160) (NSDQ: SGEN) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.